Showing results (11-20 of 40) with videos related to

Sort By:
Pageof 4
Carcinogenesis|April 7, 2000
High frequency in esophageal cancers of p53 alterations inactivating the regulation of genes involved in cell cycle and apoptosisV Robert, P Michel, J M Flaman, et al.
European Journal of Cancer (Oxford, England : 1990)|March 27, 2001
Prospective randomised study of split-course radiotherapy versus cisplatin plus split-course radiotherapy in inoperable squamous cell carcinoma of the oesophagusT Wobbes, B Baron, B Paillot, et al.
Gastroenterologie Clinique Et Biologique|May 9, 2009
Control of pelvic symptoms in patients with rectal cancer and synchronous metastasesD Tougeron, F Di Fiore, B Lefebure, et al.
Gastroenterologie Clinique Et Biologique|January 1, 1992
[Photodynamic therapy by coloring laser. Can it represent a therapeutic alternative for small epidermoid cancers of the esophagus?]P Hochain, P Ducrotté, B Paillot, et al.
British Journal of Cancer|November 13, 2008
Safety and outcome of definitive chemoradiotherapy in elderly patients with oesophageal cancerD Tougeron, F Di Fiore, S Thureau, et al.
Cytometry|December 6, 1997
Comparison between endoscopic and surgical sampling for the measurement of potential doubling time in colorectal cancerP Michel, J Hemet, M Paresy, et al.
European Journal of Gastroenterology & Hepatology|April 6, 2000
Pre-operative kinetic parameter determination of colorectal adenocarcinomas. Prognostic significanceP Michel, M Paresy, F Lepessot, et al.
Pathology, Research and Practice|July 4, 2001
Cell proliferation in colorectal adenocarcinomas: comparison between Ki-67 immunostaining and bromodeoxyuridine uptake detected by immunohistochemistry and flow cytometryF Le Pessot, P Michel, M Paresy, et al.
European Journal of Gastroenterology & Hepatology|May 20, 1999
Effect of radiation therapy on the potential doubling time of tumours in colorectal cancersP Michel, M Paresy, F Lepessot, et al.
Cancer Investigation|January 1, 1990
Randomized phase II study of a combination of cisplatin (DDP), 5-fluorouracil (5-FU), and allopurinol (HPP) versus 5-FU in advanced colorectal carcinoma. An EORTC Gastrointestinal Tract Cancer Cooperative Group studyH Bleiberg, B Vanderlinden, M Buyse, et al.
Pageof 4